Clinical Trial

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Study acronym: REVEAL
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) trial aims to determine whether lipid modification with anacetrapib 100mg daily reduces the risk of coronary death, myocardial infarction (MI) or coronary revascularization (collectively known as major coronary events) in patients with circulatory problems who have their Low-density Lipoprotein (LDL) cholesterol level treated with a statin.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2010-12-01; most recent amendment 2024-06-11.
Status change: Recruiting → Active, Not Recruiting 2014-04-16
Status change: Not Yet Recruiting → Recruiting 2011-06-21
Trial Details
NCT Number NCT01252953
Lead Sponsor University of Oxford
Collaborators: Merck Sharp & Dohme LLC
Conditions Atherosclerotic Cardiovascular Disease
Enrollment 30,449 participants
Start Date 2011-06
Primary Completion 2017-01-31 (estimated)
Study Completion 2037-01-31 (estimated)
Updated on ClinicalTrials.gov 2024-06-25